These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32881145)

  • 1. Heteromer formation between cannabinoid type 1 and dopamine type 2 receptors is altered by combination cannabinoid and antipsychotic treatments.
    Bagher AM; Young AP; Laprairie RB; Toguri JT; Kelly MEM; Denovan-Wright EM
    J Neurosci Res; 2020 Dec; 98(12):2496-2509. PubMed ID: 32881145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of Dopamine Receptor 2 Long Affects Cannabinoid Receptor 1 Signaling in a Cell Culture Model of Striatal Medium Spiny Projection Neurons.
    Bagher AM; Laprairie RB; Kelly ME; Denovan-Wright EM
    Mol Pharmacol; 2016 Jun; 89(6):652-66. PubMed ID: 27053685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoid CB1 receptors activation and coactivation with D2 receptors modulate GABAergic neurotransmission in the globus pallidus and increase motor asymmetry.
    Muñoz-Arenas G; Paz-Bermúdez F; Báez-Cordero A; Caballero-Florán R; González-Hernández B; Florán B; Limón ID
    Synapse; 2015 Mar; 69(3):103-14. PubMed ID: 25522178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.
    Laprairie RB; Bagher AM; Kelly ME; Denovan-Wright EM
    Mol Pharmacol; 2016 Mar; 89(3):364-75. PubMed ID: 26700564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CB1 receptor is required for the establishment of the hyperlocomotor phenotype in developmentally-induced hypothyroidism in mice.
    Giné E; Echeverry-Alzate V; Lopez-Moreno JA; Rodriguez de Fonseca F; Perez-Castillo A; Santos A
    Neuropharmacology; 2017 Apr; 116():132-141. PubMed ID: 28017790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid agonists stimulate [3H]GABA release in the globus pallidus of the rat when G(i) protein-receptor coupling is restricted: role of dopamine D2 receptors.
    Gonzalez B; Paz F; Florán L; Aceves J; Erlij D; Florán B
    J Pharmacol Exp Ther; 2009 Mar; 328(3):822-8. PubMed ID: 19106171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoid-induced depression of synaptic transmission is switched to stimulation when dopaminergic tone is increased in the globus pallidus of the rodent.
    Caballero-Florán RN; Conde-Rojas I; Oviedo Chávez A; Cortes-Calleja H; Lopez-Santiago LF; Isom LL; Aceves J; Erlij D; Florán B
    Neuropharmacology; 2016 Nov; 110(Pt A):407-418. PubMed ID: 27506997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral haloperidol or olanzapine intake produces distinct and region-specific increase in cannabinoid receptor levels that is prevented by high fat diet.
    Delis F; Rosko L; Shroff A; Leonard KE; Thanos PK
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):268-280. PubMed ID: 28619471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression signature in brain regions exposed to long-term psychosocial stress following acute challenge with cannabinoid drugs.
    Tomas-Roig J; Havemann-Reinecke U
    Psychoneuroendocrinology; 2019 Apr; 102():1-8. PubMed ID: 30476795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment.
    Urigüen L; García-Fuster MJ; Callado LF; Morentin B; La Harpe R; Casadó V; Lluis C; Franco R; García-Sevilla JA; Meana JJ
    Psychopharmacology (Berl); 2009 Oct; 206(2):313-24. PubMed ID: 19652957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bidirectional allosteric interactions between cannabinoid receptor 1 (CB
    Bagher AM; Laprairie RB; Toguri JT; Kelly MEM; Denovan-Wright EM
    Eur J Pharmacol; 2017 Oct; 813():66-83. PubMed ID: 28734930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus.
    Bonaventura J; Rico AJ; Moreno E; Sierra S; Sánchez M; Luquin N; Farré D; Müller CE; Martínez-Pinilla E; Cortés A; Mallol J; Armentero MT; Pinna A; Canela EI; Lluís C; McCormick PJ; Lanciego JL; Casadó V; Franco R
    Neuropharmacology; 2014 Apr; 79():90-100. PubMed ID: 24230991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis.
    Marcellino D; Carriba P; Filip M; Borgkvist A; Frankowska M; Bellido I; Tanganelli S; Müller CE; Fisone G; Lluis C; Agnati LF; Franco R; Fuxe K
    Neuropharmacology; 2008 Apr; 54(5):815-23. PubMed ID: 18262573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cannabinoid CB
    Rivas-Santisteban R; Lillo J; Raïch I; Muñoz A; Lillo A; Rodríguez-Pérez AI; Labandeira-García JL; Navarro G; Franco R
    Exp Neurol; 2023 Apr; 362():114319. PubMed ID: 36632949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered dopamine D1 and D2 receptor mRNA expression in mesencephalon from mice exposed to repeated treatments with methamphetamine and cannabinoid CB1 agonist methanandamide.
    Landa L; Jurajda M; Sulcova A
    Neuro Endocrinol Lett; 2012; 33(4):446-52. PubMed ID: 22936253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors.
    Martín AB; Fernandez-Espejo E; Ferrer B; Gorriti MA; Bilbao A; Navarro M; Rodriguez de Fonseca F; Moratalla R
    Neuropsychopharmacology; 2008 Jun; 33(7):1667-79. PubMed ID: 17957223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.
    Gamage TF; Barrus DG; Kevin RC; Finlay DB; Lefever TW; Patel PR; Grabenauer MA; Glass M; McGregor IS; Wiley JL; Thomas BF
    Pharmacol Biochem Behav; 2020 Jun; 193():172918. PubMed ID: 32247816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic deletion of dopamine D1 receptors increases the sensitivity to cannabinoid CB1 receptor antagonist-precipitated withdrawal when compared with wild-type littermates: studies in female mice repeatedly exposed to the Spice cannabinoid HU-210.
    Serrano A; Vadas E; Ferrer B; Bilbao A; Granado N; Suárez J; Pavon FJ; Moratalla R; Rodríguez de Fonseca F
    Psychopharmacology (Berl); 2021 Feb; 238(2):551-557. PubMed ID: 33410990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D2 and serotonin 5-HT1A receptor interaction in the context of the effects of antipsychotics - in vitro studies.
    Łukasiewicz S; Błasiak E; Szafran-Pilch K; Dziedzicka-Wasylewska M
    J Neurochem; 2016 May; 137(4):549-60. PubMed ID: 26876117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.